4-isobutoxycarbonylphenoxy-2,3-epoxypropane | 147539-05-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-isobutoxycarbonylphenoxy-2,3-epoxypropane
• 英文别名: 1-[4-(2-methylpropoxycarbonyl)phenoxy]-2,3-epoxypropane；isobutyl p-(2,3-epoxy)-propyloxybenzoate；2-Methylpropyl 4-(oxiran-2-ylmethoxy)benzoate
• CAS: 147539-05-7
• 化学式: C₁₄H₁₈O₄
• 分子量: 250.295
• InChiKey: NXFPAHZNMNIYMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-isobutoxycarbonylphenoxy-2,3-epoxypropane 在 2,6-二甲基吡啶 、 对甲苯磺酸 作用下， 以 乙醇 为溶剂， 生成 4-{3-[6-Amino-9-((3aR,4R,6R,6aR)-6-hydroxymethyl-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-9H-purin-8-ylsulfanyl]-2-hydroxy-propoxy}-benzoic acid isobutyl ester
  参考文献：
  名称：

  8-Substituted purine derivatives: a new class of lipid-lowering agents

  摘要：

  A series of purine derivatives have been prepared and their in vivo abilities to lower plasma total cholesterol and triglyceride levels, and to elevate high density lipoprotein (HDL) cholesterol levels in hyperlipemic rats have been tested. Some compounds, among which 8-{2-(R)-hydroxy-3-[(p-isobutoxycarbonyl)phenoxy]propylthio}adenosine 31, 8-{3-[(p-isobutoxy carbonyl)phenoxy]-2-oxopropylthio} adenosine 33 and 8-{3-[(p-isobutoxycarbonyl)phenoxy]-2-hydrazonecarboxamidepropylthio} adenosine 36 appear to be the most interesting, have been found to have both the desired profile of activity and no hepatotoxicity, when administered po at 50, 100 or 300 mg/kg. Compounds 31, 33 and 36, orally tested at the same doses in the 15-d test, lower triglyceride and VLDL/LDL (very low density lipoprotein/low density lipoprotein) cholesterol levels by 10-33% and 13-46%, respectively, and increase HDL-associated cholesterol levels by 10-32%. These molecules have been chosen for further pharmacological and toxicological evaluations.

  DOI：

  10.1016/0223-5234(94)90098-1
• 作为产物：
  描述：

  尼泊金异丁酯 、 环氧氯丙烷 在 potassium carbonate 作用下， 以 丁酮 为溶剂， 生成 4-isobutoxycarbonylphenoxy-2,3-epoxypropane
  参考文献：
  名称：

  8-Substituted purine derivatives: a new class of lipid-lowering agents

  摘要：

  A series of purine derivatives have been prepared and their in vivo abilities to lower plasma total cholesterol and triglyceride levels, and to elevate high density lipoprotein (HDL) cholesterol levels in hyperlipemic rats have been tested. Some compounds, among which 8-{2-(R)-hydroxy-3-[(p-isobutoxycarbonyl)phenoxy]propylthio}adenosine 31, 8-{3-[(p-isobutoxy carbonyl)phenoxy]-2-oxopropylthio} adenosine 33 and 8-{3-[(p-isobutoxycarbonyl)phenoxy]-2-hydrazonecarboxamidepropylthio} adenosine 36 appear to be the most interesting, have been found to have both the desired profile of activity and no hepatotoxicity, when administered po at 50, 100 or 300 mg/kg. Compounds 31, 33 and 36, orally tested at the same doses in the 15-d test, lower triglyceride and VLDL/LDL (very low density lipoprotein/low density lipoprotein) cholesterol levels by 10-33% and 13-46%, respectively, and increase HDL-associated cholesterol levels by 10-32%. These molecules have been chosen for further pharmacological and toxicological evaluations.

  DOI：

  10.1016/0223-5234(94)90098-1

文献信息

• Derivatives of (hetero)aromatic ethers and thioethers having
  申请人：Pierrel SpA

  公开号：US05470858A1

  公开（公告）日：1995-11-28

  A compound represented by the following formula I: (HET)Ar--X--CH.sub.2 --Y--CH.sub.2 --O--R (I) wherein: (HET)Ar represents a bicyclic hetero aryl nucleus which is unsubstituted or is substituted; X represents --S--; Y represents --CO--, --C.dbd.N--R.sub.2, in which R.sub.2 is hydrogen or a linear or branched alkyl having 1 to 10 carbon atoms, OH, an alkoxy having 1 to 10 carbon atoms, aryloxy, arylalkoxy, --NH.sub.2, --NHCONH.sub.2, --NHCSNH.sub.2 ; and R represents a phenyl substituted at para position with a carboxyl or a (C.sub.1 -C.sub.20) alkoxycarbonyl group in which the alkoxy group is linear or branched.

  以下是根据您提供的公式 I 的化合物 I 的中文翻译： (HET)Ar--X--CH₂--Y--CH₂--O--R (I) 其中： - (HET)Ar 表示一个双环杂芳基核，它可以是未取代的，也可以是取代的； - X 表示 --S--; - Y 表示 --CO--, --C≡N--R₂，其中 R₂ 是氢或者是一个具有 1 到 10 个碳原子的直链或支链烷基，OH，一个具有 1 到 10 个碳原子的烷氧基，芳氧基，芳烷氧基，--NH₂, --NHCONH₂, --NHCSNH₂； - R 表示在间位上带有羧基或一个 (C₁ -C₂₀) 烷氧基羰基基团的苯基，其中烷氧基是直链的或支链的。
• Derivatives of (hetero) aromatic ethers and thioethers having antihyperlipidemic activity, process for their preparation and pharmaceutical compositions containing them
  申请人：PIERREL S.p.A.

  公开号：EP0520552A1

  公开（公告）日：1992-12-30

  The novel derivatives of (hetero)aromatic ethers and thioethers represented by the following general formula I:         (HET)Ar-X-CH₂-Y-CH₂-O-R   (I) wherein: (HET)Ar represent a mono-,bi- and tri-cyclic aryl or hetero aryl nucleous possibly substituted, X represents -O- or -S-; Y represents -CO-, a linear or branched polymethylene having 0 to 8 carbon atoms with the proviso that it is not (CH₂)n in which 0

  以下是一般公式 I 所表示的 (杂)芳香醚和硫醚的新型衍生物：          (HET)Ar-X-CH₂-Y-CH₂-O-R         (I) 其中： (HET)Ar 表示可能带有取代基的单环、双环和三环芳基或杂芳基核； X 代表 -O- 或 -S-； Y 代表 -CO-，具有 0 到 8 个碳原子的直链或支链聚亚甲基，条件是当 (HET)Ar 表示可能用甲基和/或硝基取代的咪唑环，并且同时 X = S，-CH(OR₁)，其中 R₁ 是氢或来自脂肪族、芳香族或杂环羧酸的酰基，条件是当 (HET)Ar 表示鸟嘌呤、腺嘌呤或腺苷基团时，R₁ 不是氢，-C=N-R₂，其中 R₂ 是氢或具有 1 到 10 个碳原子的直链或支链烷基，OH，具有 1 到 10 个碳原子的烷氧基，芳氧基，芳烷氧基，-NH₂，-NHCONH₂，-NHCSNH₂；且 R 代表在间位带有羧基或 (C₁-C₂0) 烷氧甲酸基的苯基，其中烷氧基可以是直链或支链的，具有抗高脂血症活性。 此外，还描述了它们的制备过程和含有它们的药物组合物。
• New 8-substituted nucleoside and purine derivatives, the process for the
  申请人：Pierrel Spa

  公开号：US04774325A1

  公开（公告）日：1988-09-27

  New 8-substituted nucleoside and purine derivatives of the general formula: ##STR1## wherein R represents an amino group or an hydroxy group possibly in the corresponding keto tautomeric form, R.sub.1 is hydrogen or an amino group, R.sub.2 is hydrogen or a .beta.-D-ribofuranosyl radical wherein the primary hydroxy group and/or the two secondary hydroxy groups may be derivatized, R.sub.3 is an optionally substituted aryl or monocyclic heteroaryl radical and, X is --O-- or --S--. The new compounds have antihyperlipaemic activity.

  新的8-取代核苷和嘌呤衍生物的一般公式为：##STR1##其中R代表氨基团或羟基团，可能以相应的酮式互变形式存在，R.sub.1是氢或氨基团，R.sub.2是氢或一个β-D-核糖呋喃基团，其中主要羟基和/或两个次要羟基可以被衍生，R.sub.3是一个可选择取代的芳基或单环杂芳基团，X是--O--或--S--。这些新化合物具有抗高脂血症活性。
• Novel aryloxyalkylthioimidazoles as inhibitors of acyl-CoA: cholesterol-O-acyltransferase
  作者：M Bani、R Bormetti、W Ceccarelli、R Fiocchi、M Gobetti、M Lombroso、S Magnetti、V Olgiati、M Palladino、M Villa、E Vanotti

  DOI：10.1016/0223-5234(96)88207-9

  日期：1995.1

  A series of aryloxyalkylthioimidazoles have been synthesized and evaluated for their ability,to interfere with the enzyme acyl-CoA (cholesterol-O-acyltransferase) (ACAT, EC 2.3.1.26). Most of the molecules possessed a good in vitro ACAT inhibitory activity with IC50 values ranging between 0.1 and 2.0 mu M Some of them, eg, 2-5-[(4-isobutoxycarbonyl)phenoxy]-pentylthio} -4,5-diphenylimidazole 13, 2-3-[(4-isobutoxycarbonyl)phenoxy]-2-oximinopropylthio}-4,5-diphenylimidazole 21, 2-3-[(4-isobutoxycarbonyl)phenoxy]-2-hydrazonecarboxamidepropylthio) -4,5-diphenylimidazole 26, 2-[5-(2-pyridoxy)-pentylthio]-4,5-diphenylimidazole 40 and 2-5-[(3,5-diterbutyl-4-hydroxy)phenylthio]pentylthio}-4,5-diphenylimidazole 42, were more potent (range of activity 10-90 nM). They were also more potent with respect to the reference CI-976. When administered orally in hyperlipemic rats, at 10 and 50 mg/kg doses, some representative compounds, like 2-3-[(4-isobutoxycarbonyl)phenoxy]-2-hydroxypropylthio}-4,5-diphenylimidazole 1, 13 and 26, reduced VLDL/LDL-associated cholesterol levels by 30-50% and increased HDL cholesterol levels by 15-50%. In addition, liver accumulation of esterified cholesterol was counteracted (50-80% reduction) and liver ACAT ex vivo activity was decreased by 70-85%. Finally, the good efficacy displayed in an endogenous model of hypertriglyceridemia strongly supports the hypothesis of a good systemic availability, which constitutes one of the principal properties of a valuable ACAT inhibitor.
• New 8-substituted nucleoside and purine derivatives, the process for the preparation thereof and the pharmaceutical compositions containing them
  申请人：Pierrel S.p.A.

  公开号：EP0175325B1

  公开（公告）日：1989-03-15